Argent Biopharma Ltd (RGT) - Total Assets
Based on the latest financial reports, Argent Biopharma Ltd (RGT) holds total assets worth AU$2.47 Million AUD (≈ $1.75 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Argent Biopharma Ltd to assess how comfortably operating cash covers total debt obligations.
Argent Biopharma Ltd - Total Assets Trend (2006–2025)
This chart illustrates how Argent Biopharma Ltd's total assets have evolved over time, based on quarterly financial data. See Argent Biopharma Ltd shareholders equity for net asset value and shareholders' equity analysis.
Argent Biopharma Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Argent Biopharma Ltd's total assets of AU$2.47 Million consist of 82.3% current assets and 17.8% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 41.5% |
| Accounts Receivable | AU$375.65K | 15.2% |
| Inventory | AU$132.67K | 5.4% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Argent Biopharma Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Argent Biopharma Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Argent Biopharma Ltd's current assets represent 82.3% of total assets in 2025, an increase from 55.1% in 2006.
- Cash Position: Cash and equivalents constituted 41.5% of total assets in 2025, down from 51.3% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 7.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 15.2% of total assets.
Argent Biopharma Ltd Competitors by Total Assets
Key competitors of Argent Biopharma Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.64 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Argent Biopharma Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.19 | 0.23 | 1.09 |
| Quick Ratio | 0.18 | 0.15 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$-8.80 Million | AU$-9.44 Million | AU$261.55K |
Argent Biopharma Ltd - Advanced Valuation Insights
This section examines the relationship between Argent Biopharma Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.85 |
| Latest Market Cap to Assets Ratio | 1.21 |
| Asset Growth Rate (YoY) | -77.1% |
| Total Assets | AU$2.47 Million |
| Market Capitalization | $2.99 Million USD |
Valuation Analysis
Above Book Valuation: The market values Argent Biopharma Ltd's assets above their book value (1.21x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Argent Biopharma Ltd's assets decreased by 77.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Argent Biopharma Ltd (2006–2025)
The table below shows the annual total assets of Argent Biopharma Ltd from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$2.47 Million ≈ $1.75 Million |
-77.12% |
| 2024-06-30 | AU$10.79 Million ≈ $7.63 Million |
+8.05% |
| 2023-06-30 | AU$9.98 Million ≈ $7.06 Million |
-46.20% |
| 2022-06-30 | AU$18.56 Million ≈ $13.13 Million |
-23.43% |
| 2021-06-30 | AU$24.24 Million ≈ $17.15 Million |
+205.66% |
| 2020-06-30 | AU$7.93 Million ≈ $5.61 Million |
-38.99% |
| 2019-06-30 | AU$13.00 Million ≈ $9.20 Million |
-35.00% |
| 2018-06-30 | AU$19.99 Million ≈ $14.15 Million |
-3.97% |
| 2017-06-30 | AU$20.82 Million ≈ $14.73 Million |
+27.25% |
| 2016-06-30 | AU$16.36 Million ≈ $11.58 Million |
+549.08% |
| 2015-06-30 | AU$2.52 Million ≈ $1.78 Million |
-49.37% |
| 2014-06-30 | AU$4.98 Million ≈ $3.52 Million |
-42.80% |
| 2013-06-30 | AU$8.70 Million ≈ $6.16 Million |
+777.08% |
| 2012-06-30 | AU$992.36K ≈ $702.16K |
+31.96% |
| 2012-04-30 | AU$752.00K ≈ $532.09K |
-31.25% |
| 2011-06-30 | AU$1.09 Million ≈ $773.95K |
-92.26% |
| 2010-06-30 | AU$14.13 Million ≈ $10.00 Million |
-13.93% |
| 2009-06-30 | AU$16.42 Million ≈ $11.62 Million |
+521.79% |
| 2008-06-30 | AU$2.64 Million ≈ $1.87 Million |
-44.89% |
| 2007-06-30 | AU$4.79 Million ≈ $3.39 Million |
-10.78% |
| 2006-06-30 | AU$5.37 Million ≈ $3.80 Million |
-- |
About Argent Biopharma Ltd
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I c… Read more